Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Dysregulation of the MET tyrosine kinase receptor drives oncogenesis in various cancers.
• MET-targeted therapies are under development for non-small cell lung cancer (NSCLC), but clinical success is limited.
• Effective predictive biomarkers are needed to optimize patient selection for MET-targeted treatments.

Purpose of the Study:

• To discuss the concept of companion diagnostic (CDx) assays.
• To focus on FDA-approved MET-targeted therapies for NSCLC.
• To highlight the importance of predictive biomarkers in MET-targeted cancer therapy.

Main Methods:

• Review of current MET-targeted therapies and their associated diagnostic assays.
• Analysis of genetic alterations in MET, including exon 14 skipping and amplification.
• Evaluation of fluorescence in situ hybridization (FISH) for detecting MET amplification (MET/CEP7 ratio).

Main Results:

• Capmatinib is the only approved MET-targeted drug with a CDx assay for NSCLC with MET exon 14 skipping.
• MET amplification is a resistance mechanism in EGFR-mutated NSCLC.
• The MET/CEP7 ratio detected by FISH shows strong predictive properties for MET amplification, excluding polysomy.

Conclusions:

• Companion diagnostic assays are essential for the effective use of MET-targeted therapies in NSCLC.
• Accurate identification of MET alterations, such as exon 14 skipping and amplification, guides treatment decisions.
• Further development and validation of predictive biomarkers are critical for advancing MET-targeted cancer treatment.